Gebelik ve Tiroid Hastalıkları
Özet
Gebelik döneminde tiroid hastalıkları, diyabetten sonra en sık rastlanan ikinci endokrin bozukluk olup anne ve fetüs sağlığı üzerinde kritik etkilere sahiptir. Hamilelikle birlikte tiroid hormonu üretimi ve iyot ihtiyacı yaklaşık %50 oranında artış gösterir. İyot yeterliliği olan bölgelerde hipotiroidizmin en yaygın nedeni Hashimoto tiroiditi iken, hipertiroidizmin temel sebebi Graves hastalığıdır. Ayrıca, gebeliğin ilk yarısında yüksek hCG seviyelerine bağlı olarak geçici gestasyonel tirotoksikoz da sıklıkla görülür. Tanı aşamasında trimester bazlı TSH referans aralıklarının kullanılması esastır; popülasyona özel bir aralık yoksa TSH üst sınırı 4.0 mU/L olarak kabul edilir. Tedavi edilmeyen hipotiroidizm ve hipertiroidizm; erken doğum, preeklampsi, düşük doğum ağırlığı ve fetüste bilişsel gelişim bozukluğu gibi ciddi komplikasyonlara yol açabilir. Aşikar hipotiroidizm tiroid hormon replasmanı ile tedavi edilirken, Graves hastalığında ilk trimesterde PTU, sonrasında ise MMI tercih edilir. Dünya Sağlık Örgütü, gebelik ve emzirme sürecinde günlük 250 mcg iyot alımını önermektedir. Tiroid nodülleri ve diferansiye tiroid kanserlerinin seyri genellikle gebelikten olumsuz etkilenmez ve cerrahi müdahale gerekirse en güvenli dönem ikinci trimesterdir. Bu süreçlerin takibi multidisipliner bir sağlık ekibiyle yürütülmelidir.
Thyroid diseases during pregnancy are the second most common endocrine disorder after diabetes and have critical impacts on maternal and fetal health. With pregnancy, thyroid hormone production and iodine requirements increase by approximately 50%. While Hashimoto's thyroiditis is the most common cause of hypothyroidism in iodine-sufficient areas, Graves' disease is the primary cause of hyperthyroidism. Additionally, transient gestational thyrotoxicosis is frequently observed in the first half of pregnancy due to high hCG levels. Using trimester-specific TSH reference ranges is essential for diagnosis; if no population-specific range is available, the upper TSH limit is accepted as 4.0 mU/L. Untreated hypothyroidism and hyperthyroidism can lead to severe complications such as preterm birth, preeclampsia, low birth weight, and impaired fetal cognitive development. Overt hypothyroidism is treated with thyroid hormone replacement, whereas for Graves' disease, PTU is preferred in the first trimester, followed by MMI in subsequent trimesters. The World Health Organization recommends a daily iodine intake of 250 mcg during pregnancy and lactation. The course of thyroid nodules and differentiated thyroid cancers is generally not adversely affected by pregnancy, and if surgical intervention is required, the second trimester is the safest period. Management of these conditions must be conducted by a multidisciplinary healthcare team.
Referanslar
Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel SJ, Peeters RP, Sullivan S. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017 Mar;27(3):315-389.
Yim CH. Update on the Management of Thyroid Disease during Pregnancy. Endocrinol Metab (Seoul). 2016 Sep;31(3):386-391.
Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol. 2013 Nov;1(3):238-49.
Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev. 1997 Jun;18(3):404-33.
Klein RZ, Haddow JE, Faix JD, Brown RS, Hermos RJ, Pulkkinen A, Mitchell ML. Prevalence of thyroid deficiency in pregnant women. Clin Endocrinol (Oxf). 1991 Jul;35(1):41-6.
Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev. 2010 Oct;31(5):702-55.
Weeke J, Dybkjaer L, Granlie K, Eskjaer Jensen S, Kjaerulff E, Laurberg P, Magnusson B. A longitudinal study of serum TSH, and total and free iodothyronines during normal pregnancy. Acta Endocrinol (Copenh). 1982 Dec;101(4):531-7.
Soldin OP, Tractenberg RE, Hollowell JG, Jonklaas J, Janicic N, Soldin SJ. Trimester-specific changes in maternal thyroid hormone, thyrotropin, and thyroglobulin concentrations during gestation: trends and associations across trimesters in iodine sufficiency. Thyroid. 2004 Dec;14(12):1084-90.
Glinoer D, Spencer CA. Serum TSH determinations in pregnancy: how, when and why? Nat Rev Endocrinol. 2010 Sep;6(9):526-9.
Lee RH, Spencer CA, Mestman JH, Miller EA, Petrovic I, Braverman LE, Goodwin TM. Free T4 immunoassays are flawed during pregnancy. Am J Obstet Gynecol. 2009 Mar;200(3):260.e1-6.
Glinoer D. The importance of iodine nutrition during pregnancy. Public Health Nutr. 2007 Dec;10(12A):1542-6.
Berghout A, Wiersinga W. Thyroid size and thyroid function during pregnancy: an analysis. Eur J Endocrinol. 1998 May;138(5):536-42.
Shi X, Han C, Li C, Mao J, Wang W, Xie X, Li C, Xu B, Meng T, Du J, Zhang S, Gao Z, Zhang X, Fan C, Shan Z, Teng W. Optimal and safe upper limits of iodine intake for early pregnancy in iodine-sufficient regions: a cross-sectional study of 7190 pregnant women in China. J Clin Endocrinol Metab. 2015 Apr;100(4):1630-8.
Glinoer D, de Nayer P, Bourdoux P, Lemone M, Robyn C, van Steirteghem A, Kinthaert J, Lejeune B. Regulation of maternal thyroid during pregnancy. J Clin Endocrinol Metab. 1990 Aug;71(2):276-87.
Mandel SJ, Larsen PR, Seely EW, Brent GA. Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med. 1990 Jul 12;323(2):91-6.
Momotani N, Noh J, Oyanagi H, Ishikawa N, Ito K. Antithyroid drug therapy for Graves' disease during pregnancy. Optimal regimen for fetal thyroid status. N Engl J Med. 1986 Jul 03;315(1):24-8.
Roti E, Minelli R, Salvi M. Clinical review 80: Management of hyperthyroidism and hypothyroidism in the pregnant woman. J Clin Endocrinol Metab. 1996 May;81(5):1679-82.
Van Dijke CP, Heydendael RJ, De Kleine MJ. Methimazole, carbimazole, and congenital skin defects. Ann Intern Med. 1987 Jan;106(1):60-1.
Bahn RS, Burch HS, Cooper DS, Garber JR, Greenlee CM, Klein IL, Laurberg P, McDougall IR, Rivkees SA, Ross D, Sosa JA, Stan MN. The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid. 2009 Jul;19(7):673-4.
Lydakis C, Lip GY, Beevers M, Beevers DG. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens. 1999 Jun;12(6):541-7.
Kung AW, Chau MT, Lao TT, Tam SC, Low LC. The effect of pregnancy on thyroid nodule formation. J Clin Endocrinol Metab. 2002 Mar;87(3):1010-4.
Glinoer D, Soto MF, Bourdoux P, Lejeune B, Delange F, Lemone M, Kinthaert J, Robijn C, Grun JP, de Nayer P. Pregnancy in patients with mild thyroid abnormalities: maternal and neonatal repercussions. J Clin Endocrinol Metab. 1991 Aug;73(2):421-7.
Moosa M, Mazzaferri EL. Outcome of differentiated thyroid cancer diagnosed in pregnant women. J Clin Endocrinol Metab. 1997 Sep;82(9):2862-6.
Tan GH, Gharib H, Goellner JR, van Heerden JA, Bahn RS. Management of thyroid nodules in pregnancy. Arch Intern Med. 1996 Nov 11;156(20):2317-20.
Abalovich M, Gutierrez S, Alcaraz G, Maccallini G, Garcia A, Levalle O. Overt and subclinical hypothyroidism complicating pregnancy. Thyroid. 2002 Jan;12(1):63-8.
Kriplani A, Buckshee K, Bhargava VL, Takkar D, Ammini AC. Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy. Eur J Obstet Gynecol Reprod Biol. 1994 May 18;54(3):159-63.
Poppe K, Velkeniers B, Glinoer D. The role of thyroid autoimmunity in fertility and pregnancy. Nat Clin Pract Endocrinol Metab. 2008 Jul;4(7):394-405.
Bussen S, Steck T. Thyroid autoantibodies in euthyroid non-pregnant women with recurrent spontaneous abortions. Hum Reprod. 1995 Nov;10(11):2938-40.
